Catalog No.S1988 Synonyms: NSC 6498, NSC 70461
Molecular Weight(MW): 170.23
Propylthiouracil is a thyroperoxidase and 5'-deiodinase inhibitor, used to treat hyperthyroidism.
Purity & Quality Control
|Description||Propylthiouracil is a thyroperoxidase and 5'-deiodinase inhibitor, used to treat hyperthyroidism.|
|In vivo||Propylthiouracil-induced hypothyroidism reduces oxidative damage in the lung, hepatic, renal and ileal tissues probably due to hypometabolism in rats, which is associated with decreased production of reactive oxygen metabolites and enhancement of antioxidant mechanisms.  Propylthiouracil-induced congenital hypothyroidism upregulates vimentin phosphorylation and depletes antioxidant defenses in immature rat testis.  Propylthiouracil results in lesser concentrations of thyroxine (T4) and triiodothyronine (T3), greater concentrations of follicle stimulating hormone (FSH) and luteinizing hormone (LH) peptides, and increase in steroidogenic gene expression after 12 hours and 48 hours in zebrafish. Propylthiouracil-induced hypothyroidism is associated with increased tolerance of the isolated rat heart toischaemia-reperfusion.  Propylthiouracil (PTU) dramatically reduces thyroid hormones on PND21 and produced deficits in body weight that persisted to adulthood in developing rats.  Propylthiouracil inhibits both the synthesis of thyroid hormones in the thyroid gland and the conversion of T4 to its active form, T3. Propylthiouracil treatment significantly increases circulating TSH at both P3 and P7. Propylthiouracil exposure of adult rats, at a dose inducing modest reductions in circulating T4 concentrations and no significant effect on brain BDNF, significantly alteres the thyroid hormones and hippocampal BDNF levels in the offspring at 3 and 7 d after birth. |
-  Sener G, et al. J Endocrinol,?006, 189(2), 257-269.
-  Zamoner A, et al. J Mol Endocrinol,?008, 40(3), 125-135.
-  Liu C, et al. Environ Sci Technol,?011, 45(2), 769-775.
|In vitro||DMSO||34 mg/mL (199.72 mM)|
|Ethanol||19 mg/mL (111.61 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Synonyms||NSC 6498, NSC 70461|
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT01056419||Unknown status||Graves Ophthalmopathy||Ankara University||January 2009||Phase 4|
|NCT00846755||Completed||Thyroid Disease|Pregnancy||Ospedale V. Fazzi||March 2005||--|
|NCT01436994||Completed||Paediatric Thyrotoxicosis||Newcastle-upon-Tyne Hospitals NHS Trust||July 2004||Phase 3|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.